Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches? - Wikidata - awgldk - TriplyDB

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

http://www.wikidata.org/entity/Q53377800

about

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

http://www.wikidata.org/entity/Q53377800

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

@en

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

@nl

type

label

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

@en

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

@nl

prefLabel

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

@en

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

@nl

P1433

Q53377800-086C0716-8939-4887-A07A-64BA5D618BC2

P1476

Q53377800-C4DFDB54-C908-485D-9072-ACF8363BB0CA

P2093

Q53377800-6DB4C61C-BB5D-423A-BBFF-F364D3A6F644

P2860

Q53377800-5050F5EC-F6D8-49E7-8E56-251DF001537B

Q53377800-585AD300-E915-4726-9B0A-669BAD410938

Q53377800-6AC35AB5-C119-43C3-B7AB-91EE27433385

Q53377800-6FBF6AF1-7EE2-48E8-AD35-AB2F5936ACA2

Q53377800-7FA28C89-B727-4630-B90F-B26A09F4A6C8

Q53377800-9D456533-9E7F-4586-891E-24BB12250DEA

Q53377800-9FCE5F91-BC84-4CD4-B857-6731B3D801BC

Q53377800-B9D1F54A-F28F-461A-9AC6-E7488938D67D

Q53377800-BB843086-DEB0-4952-B894-4717FAC08679

Q53377800-E8B87A30-D87C-46C0-9374-CC5919269A30

P304

Q53377800-A72A898B-23B3-45DD-AB54-61164CAA6E47

P31

Q53377800-6E507A43-3C98-47A4-A436-4AD300D1A3BB

Q53377800-787ddc1d-2807-40bf-a52a-008a490cfece

P356

Q53377800-B0B660A5-F817-4FE7-B60C-B72EACCBC01D

P433

Q53377800-8FD4F6AC-940B-4073-BE86-81091927FEB8

P478

Q53377800-A46024C4-2747-4318-B4A1-053AECB3D630

P50

Q53377800-BF389CD4-8EC8-4186-B1ED-592E2ADF7DB9

P577

Q53377800-A83A5C93-2D0F-4E74-B167-E7EB6BD00C69

P698

Q53377800-F43EA4A9-3BEF-44EE-A554-8838F56F1C28

P356

P1433

Annals of Oncology

P1476

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

@en

P2093

J F Seymour

http://www.w3.org/2001/XMLSchema#string

P2860

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Management of adverse events associated with idelalisib treatment: expert panel opinion.

P304

920-921

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDX103

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Constantine S. Tam

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28379289

http://www.w3.org/2001/XMLSchema#string